Johns Hopkins Medicine and Unbound Medicine have expanded the Johns Hopkins Psychiatry POC-IT Guide to include new clinical guidance on psychedelic medicine, marking a significant update to the digital resource used by clinicians and trainees worldwide.
The new content was developed by experts at the Johns Hopkins Center for Psychedelic and Consciousness Research (CPCR) and provides evidence-based recommendations to support clinical decision-making in a rapidly evolving area of psychiatric treatment. Psychedelic-assisted therapies have gained increased research attention in recent years, particularly for complex mental health conditions such as treatment-resistant depression and post-traumatic stress disorder (PTSD).
A substantial proportion of patients with major depression and PTSD do not respond to conventional treatments, underscoring the need for alternative therapeutic approaches. Ongoing clinical trials have demonstrated therapeutic potential for psychedelic-assisted treatments, with studies continuing that could lead to future regulatory approvals.
The updated Psychiatry Guide is intended to help healthcare professionals navigate emerging research while emphasizing patient screening, clinician-patient communication, and safe, evidence-based care. The guidance was informed by recent discussions at a Johns Hopkins panel examining the expanding role of clinicians in managing complex psychiatric conditions.
Beyond psychedelic medicine, the latest update includes patient education materials, alignment with DSM-5-TR diagnostic criteria, and updates to drug information sections. These additions are designed to support both clinical use and patient engagement.
Click here to read the original press release.
